Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial.

ABSTRACT:

Introduction

Patients with liver cirrhosis are often diagnosed late and once complications are present, the 2-year survival is 50%. Increasing evidence supports systemic inflammation and metabolic dysfunction in the hepatic stellate cell as key drivers of progression of cirrhosis. However, there is no registered medication, that targets inflammation and cellular dysfunction in the liver.

Methods and analysis

In a randomised double-blind and placebo-controlled trial with atorvastatin for liver cirrhosis, we aim to investigate clinical endpoints of survival, hospitalisations and safety, but also exploratory endpoints of genomics and protein functions in the liver.

Ethics and dissemination

There is no registered medication that actively prevents development of complicati

SUBMITTER: Kimer N 

PROVIDER: S-EPMC7045122 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature